MedTrace Logo

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in France

NCT01291394 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 223

Last updated 2017-12-26

No results posted yet for this study

Summary

This is a National, Multicentre, Observational Registry to study adherence and long term outcomes of therapy in paediatric subjects using Easypod™ electromechanical device for growth hormone treatment from hospitals in France and to assess the level of adherence of subjects receiving SAIZEN® via Easypod™.

Conditions

  • Growth Disorders

Interventions

DEVICE

Easypod™

Saizen (Somatotropin) as per Summary of Product Characteristics administered by Easypod™

Sponsors & Collaborators

  • Merck Serono S.A.S, France

    collaborator INDUSTRY

  • Merck KGaA, Darmstadt, Germany

    lead INDUSTRY

Principal Investigators

  • Medical Director · MGS Division, Merck Serono s.a.s, France, an affiliate of Merck KGaA, Darmstadt, Germany

Eligibility

Min Age
2 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • France

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01291394 on ClinicalTrials.gov